Esperion Announces Public Offering of Common Stock

ANN ARBOR — The cholesterol-fighting drug developer Esperion Therapeutics Inc. (NASDAQ:ESPR) Tuesday announced the proposed sale of $150 million of its common stock in an underwritten public offering.

Esperion also expects to grant the underwriters a 30-day option to purchase up to $22.5 million of additional shares of its common stock.

The company said it would use the net proceeds of the offering to continue the research into its novel cholesterol-fighting drugs. Esperion’s research involves new drugs that allow for lower doses of today’s statin drugs, since statins can cause side effects such as muscle pain and weakness, while still cutting artery-clogging cholesterol.

The securities described may be offered by Esperion pursuant to a shelf registration statement on Form S-3 including a base prospectus. A preliminary prospectus supplement related to the offering and a final prospectus supplement related to the offering will be filed with the SEC and will be available on the SEC’s website at http://www.sec.gov.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s